78 related articles for article (PubMed ID: 31526159)
1. A Novel Dual-Fc Bispecific Antibody with Enhanced Fc Effector Function.
Zhou F; Ben Y; Jiang H; Tan S; Mu G; Zha Z; Dong S; Huang S; Zhou Y; Jin Y; Chiu ML
Biochemistry; 2024 Apr; 63(8):958-968. PubMed ID: 38426700
[TBL] [Abstract][Full Text] [Related]
2. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.
Gray E; Ulrich M; Epp A; Younan P; Sahetya D; Hensley K; Allred S; Huang LY; Hahn J; Gahnberg K; Treuting PM; Trueblood ES; Gosink JJ; Thurman R; Wo S; Spahr K; Haass EJ; Snead K; Miller D; Padilla M; Smith AJ; Frantz C; Schrum JP; Nazarenko N; Gardai SJ
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793853
[TBL] [Abstract][Full Text] [Related]
3. Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins.
Surowka M; Schaefer W; Klein C
MAbs; 2021; 13(1):1967714. PubMed ID: 34491877
[TBL] [Abstract][Full Text] [Related]
4. Bispecific Antibodies: From Research to Clinical Application.
Ma J; Mo Y; Tang M; Shen J; Qi Y; Zhao W; Huang Y; Xu Y; Qian C
Front Immunol; 2021; 12():626616. PubMed ID: 34025638
[TBL] [Abstract][Full Text] [Related]
5. Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies.
van der Horst HJ; Nijhof IS; Mutis T; Chamuleau MED
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33086644
[TBL] [Abstract][Full Text] [Related]
6. Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices.
Dengl S; Mayer K; Bormann F; Duerr H; Hoffmann E; Nussbaum B; Tischler M; Wagner M; Kuglstatter A; Leibrock L; Buldun C; Georges G; Brinkmann U
Nat Commun; 2020 Oct; 11(1):4974. PubMed ID: 33009381
[TBL] [Abstract][Full Text] [Related]
7. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
[TBL] [Abstract][Full Text] [Related]
8. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.
Moore GL; Bautista C; Pong E; Nguyen DH; Jacinto J; Eivazi A; Muchhal US; Karki S; Chu SY; Lazar GA
MAbs; 2011; 3(6):546-57. PubMed ID: 22123055
[TBL] [Abstract][Full Text] [Related]
9. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
[TBL] [Abstract][Full Text] [Related]
10. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
11. DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity.
Sustmann C; Dickopf S; Regula JT; Kettenberger H; Mølhøj M; Gassner C; Weininger D; Fenn S; Manigold T; Kling L; Künkele KP; Schwaiger M; Bossenmaier B; Griese JJ; Hopfner KP; Graff-Meyer A; Stahlberg H; Ringler P; Lauer ME; Brinkmann U; Schaefer W; Klein C
MAbs; 2019; 11(8):1402-1414. PubMed ID: 31526159
[TBL] [Abstract][Full Text] [Related]
12. The use of CrossMAb technology for the generation of bi- and multispecific antibodies.
Klein C; Schaefer W; Regula JT
MAbs; 2016; 8(6):1010-20. PubMed ID: 27285945
[TBL] [Abstract][Full Text] [Related]
13. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
